Join the 'Zofran' group to help and get support from people like you.
Posted 30 Jun 2017 by Drugs.com
FRIDAY, June 30, 2017 – Your friends are excited to ride that monster roller coaster, but just looking at it makes you queasy. Is there anything you can do to quell your motion sickness so you can join in the fun? If you suffer from motion sickness, there are some ways to deal with it, one doctor says, though riding roller coasters isn't likely an activity you'll ever love. Motion sickness can ...
Posted 19 Aug 2015 by Drugs.com
WEDNESDAY, Aug. 19, 2015 – Expectant mothers hit hard with nausea and vomiting in early pregnancy don't need to muddle through debilitating symptoms, new recommendations say. In updating 11-year-old guidelines on treating morning sickness, the American College of Obstetricians and Gynecologists (ACOG) now suggests women pair vitamin B6 and the antihistamine doxylamine to treat persistent, ...
FDA Medwatch Alert: Metoclopramide Injection And Ondansetron Injection by Hospira: Recall - Glass Strand Particulates Caused By Glass Supplier
Posted 3 Oct 2013 by Drugs.com
ISSUE: Hospira, Inc. announced it initiated a voluntary nationwide recall of one lot of Metoclopramide Injection, USP, 10 mg/2 mL (5 mg/mL)and two lots of Ondansetron Injection, USP, 4 mg/2 mL, (2 mg/mL). This action is due to a confirmed vial defect where glass particulate matter (glass strands) were identified as being affixed to the inside of the vial walls. There is potential for the glass pa ...
FDA Medwatch Alert: Ondansetron (Zofran) 32 mg, Single Intravenous (IV) Dose: Updated Safety Communication – Product Removal due to Potential For Serious Cardiac Risks
Posted 4 Dec 2012 by Drugs.com
ISSUE: FDA is notifying health care professionals that the 32 mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risks. BACKGROUND: The 32 mg, single IV dose of Zofran had been used to prevent chemotherapy-induced nausea and vomiting. A previous Drug Safety Communication (DSC), issued ...
FDA Medwatch Alert: Ondansetron (Zofran) IV: Drug Safety Communication - QT prolongation
Posted 3 Jul 2012 by Drugs.com
ISSUE: The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a 32 mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) may affect the electrical activity of the heart (QT interval prolongation), which could pre-dispose patients to develop ...
FDA Medwatch Alert: Zofran (ondansetron): Drug Safety Communication - Risk of Abnormal Heart Rhythms
Posted 15 Sep 2011 by Drugs.com
ISSUE: FDA notified healthcare professionals and patients of an ongoing safety review and labeling changes for the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and generics). Ondansetron may increase the risk of developing prolongation of the QT interval of the electrocardiogram, which can lead to an abnormal and potentially fatal heart rhythm, including Torsade de Pointes. ...
Related Condition Support Groups
Nausea / Vomiting, Alcohol Dependence, Gastroenteritis, Nausea / Vomiting - Chemotherapy Induced, Nausea / Vomiting - Postoperative, Nausea / Vomiting - Radiation Induced, Obsessive Compulsive Disorder, Postanesthetic Shivering, Pruritus